Radiopharmaceutical Market Opportunities and Forecast, 2034

Market Overview for Radiopharmaceuticals for 2024 to 2034

Radiopharmaceuticals, in the limelight of heavy healthcare expenditures by affluent economies, is taking long strides in scientific innovations. FMI report suggests an overall global valuation of US$ 6972.1 million in 2024.

Increased awareness of the benefits of radioisotope medications has slated this valuation to surpass US$ 11635 million by 2034, growing at a CAGR of 3.40% for the forecast period of 2024 to 2034.

Attributes	Details
Radiopharmaceutical Market Value for 2024	US$ 6972.1 million
Projected Market Value for 2034	US$ 11635 million
Value-based CAGR from 2024 to 2034	3.40%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Radiopharmaceuticals Industry Analysis

Pandemic-induced readiness in the healthcare and medicare sector, pushing public as well as private entities to invest hefty financial capital in the research and development of new medications, drugs, vaccines, etc.
Prevalence of chronic diseases in developing and developed economies with well-established healthcare infrastructure, robust reimbursement policies, affluent per capita incomes, and increasing health consciousness.
The industry-academia collaboration, in the past few decades, especially in the field of radio isotopic medication, bringing into the international marketplace novel formulations of medications, drugs, etc.
The growing reliance on targeted therapies involving radionuclide-based therapies in cancer treatments to mitigate or control the spread of infection from one specific part of the body to another.
Adoption of radiopharmaceuticals such as Radium-223, Lutetium-177, Samarium-153, and Actinium-225 to cure metastatic prostate cancer by medical professionals all over the world.
Usual side-effects and allergic reactions faced by the patients after the dosage of radiopharmaceuticals to study a specific tissue or organ of the body, making patients hesitant to trust the efficacy of these treatments.
Frequent visits to the hospital for radio chemotherapy due to its small dosages and prolonged treatment process are creating a sense of hesitancy in the minds of patients seeking this treatment which is affecting the adoption
High costs, inefficient healthcare infrastructure, and long waiting periods for treatments, in underdeveloped parts of the world, are also impeding the market growth. Besides this, the lack of unskilled medical professionals and poor government healthcare policies also hinder market growth.

Consumption Analysis of Radiopharmaceuticals

Cancer patients, across the world, form one of the largest consumer pools in the market for radiopharmaceuticals. This consumer group uses radionuclide-infused medications, drugs, vaccines, etc. to mitigate or stop the spread of tumors in the body.
The sales of radiopharmaceuticals are also increasing among patients dealing with cardiovascular diseases such as myocardial perfusion imaging for coronary artery disease, etc. With more than half of the world population having these issues, this sale is very likely to surge in the coming future.
Industry-wise, healthcare institutions, both public as well as private ones, procure radiopharmaceuticals for medical imaging services such as PET scans, SPECT scans, and other nuclear medicine procedures.
Medical imaging centers also generate a significant demand for radiopharmaceuticals, such as Radium-223, Lutetium-177, Samarium-153, and Actinium-225, for various scans and tests.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Category-wise Insights

Cancer Therapies Involving Technetium-99 to Gain Popularity

Technetium-99, a metastable nuclear isomer of technetium-99, is one of the most commonly used isotopes in medical imaging. It is accounted to hold a share of 47.20% in the radiopharmaceutical market.

Attributes	Details
Radioisotope	Technetium-99
Market Share (2024)	47.20%

The demand for Technetium-99, in the modern medicare sector, is touching the skies as it is usually used in single-photon emission computed tomography (SPECT) imaging. This enables medical practitioners to create detailed images of internal organs and tissues.
Technietium-99-based radiopharmaceuticals can also be combined with other compounds and medications to detect tumors and infections in a wide range of medical conditions, including cardiovascular diseases, bone disorders, renal dysfunction, and cancer.

Oncology Treatments to Benefit from Radiopharmaceutical Medications

Attributes	Details
Application	Oncology
Market Share (2024)	51.40%

According to World Cancer Research Fund International’s survey, 18.1 million people are diagnosed with cancer currently. This vast number has generated a huge demand for radiopharmaceuticals as it is one of the most important components in cancer diagnosis.
Radiopharmaceuticals’ efficacy and effectiveness in cancer treatments and the trust shown by medical professionals in it for mitigating tumors, in medical imaging, and for regular monitoring is also augmenting its adoption worldwide.

Country-wise Analysis

Asian countries are set to become some of the lucrative markets for radiopharmaceuticals in the coming future. The growth rates for these countries have been jotted down below. Huge population, government policies, the prevalence of chronic diseases, such as cancer, and rising medical tourism are some of the main reasons for this growth.

Countries	CAGR (2024 to 2034)
India	5.40%
Malaysia	3.90%
Indonesia	3.70%
Thailand	3.20%
Spain	2.90%

Government Policies in India to Become a Boon for the Radiopharmaceuticals Industry

The Indian radiopharmaceutical industry is slated to grow at a healthy CAGR of 5.40% for the forecasted period.

In the last few years, government policies in India regarding medical inclusion of the poor and middle class have changed the overall health infrastructure of the country. With the recent pandemic, this progress got a substantial boost.
This medicare transformation has helped healthcare facilities across the country to easily adopt sophisticated methodologies involving the use of radiopharmaceuticals to treat cancers and other chronic diseases.

Malaysian Oncology to Benefit from Medical Tourism Activities

Malaysia is one of the most lucrative markets for radiopharmaceuticals. For the period of 2024 to 2034, the market is very likely to grow at a CAGR of 3.90%.

The Malaysian market for radiopharmaceuticals is booming, thanks to its expanding medical tourism industry in the past few years. Each year, more than one million patients flock to the nation to take advantage of its advanced medical facilities.
This cyclic migration of patients automatically generates substantial demand for radiopharmaceutical medications, drugs, vaccines, etc. Radiopharmaceuticals are also needed in medical imaging and regular monitoring of patients' overalls.

Breast and Cervical Cancer to Augment the Adoption of Radiopharmaceuticals in Indonesia

The Indonesian market for radiopharmaceuticals is set to grow at a sluggish CAGR of 3.70% through 2034.

According to the National Center for Biotechnology Information, 3.80 million of the 270 million Indonesian population is dealing with cancer. This presents a great opportunity for pharmaceutical companies involved in the manufacturing of radiopharmaceuticals to cater to the medication requirements of healthcare facilities in Indonesia.
Regular awareness policies by the Minister of Health of the Republic of Indonesia have also increased the adoption of radiopharmaceuticals as people are regularly conducting full-body checkups for early detection of cancer and other fatal diseases.

Cancer-treating Radiopharmaceuticals Gain Ground in Thailand

The Thai radiopharmaceutical market also has a promising future like the other Asian countries. It is very much likely to progress at 3.20% CAGR through 2034.

The International Atomic Energy Association, under its new project, has started the clinical use and distribution of lutetium-177 (Lu-177)-DOTATATE - a radiopharmaceutical for treating neuroendocrine tumors, across various countries including Thailand.
Distributions like this have made the adoption and implementation of radiopharmaceuticals in Thailand very feasible and affordable for the middle-class population, which in turn is amplifying the market growth.

Rising Incidences of Chronic Diseases to Augment Market Growth in Spain

The Spanish market for radiopharmaceuticals is accounted to grow at a CAGR of 2.90% for 2024 to 2034.

Just like the majority of European and Western countries, Spain is currently dealing with the problem of rising incidences of chronic diseases such as cardiovascular diseases, cancer, obesity, etc.
This growing prevalence in the Spanish general population has generated great demand in the international market for radiopharmaceuticals.

Competitive Landscape

The market for radiopharmaceuticals is still in its nascent stages with very few companies dominating the international marketplace. However, with medical advancements and the proliferation of these methodologies in the medical world, the requirement of radiopharmaceuticals will soon experience a drastic surge. This will provide excellent opportunities for new players to enter the market.

Some of the prominent companies in the market are Bayer AG, Bracco Imaging S.p.A., Cardinal Health, Inc., Eli Lilly and Company (Eli Lilly), Curium Pharma, Lantheus Holdings, Inc., Novartis AG, Nordion (Canada) Inc., etc. These companies provide radiopharmaceuticals to healthcare facilities such as hospitals, ambulatory surgical centers, clinics, specialty hospitals, etc.

Innovation and keeping up with the latest medical technology are the key components in this market. This is the reason why, these companies are found to be investing millions of dollars in the development of novel radiopharmaceuticals with better efficiency.

Besides this, collaborative efforts with government bodies are also being carried out to make the offering more affordable, feasible, and easily available, especially in developing and underdeveloped parts of the world.

Recent Developments

In February 2024, Bayer solidified a partnership with PanTera, obtaining actinium-225 for pioneering radiopharmaceuticals. This collaboration marked PanTera's debut with a major pharmaceutical firm, commencing clinical trial provision in the latter half of the year.
In March 2024, Ariceum Therapeutics inaugurated its Berlin-based radiopharmaceutical laboratory, enabling internal R&D for upcoming pipeline candidates
In March 2024, Ratio Therapeutics Inc. revealed an extended manufacturing deal with PharmaLogic, a renowned CDMO for radiopharmaceuticals. The partnership aimed to expedite the production and launch of Ratio's cutting-edge radiotherapies, particularly its FAP-targeted candidate.
In March 2024, Telix Pharmaceuticals acquired ARTMS Inc. for up to $82 million, expanding its radiopharmaceutical capabilities. The deal provided access to advanced isotope production technology, a manufacturing facility, and a reserve of ultrapure rare metals, bolstering Telix's presence in the industry.

Key Companies

Bayer AG
Bracco Imaging S.p.A.
Cardinal Health, Inc.
Eli Lilly and Company (Eli Lilly)
Curium Pharma
Lantheus Holdings, Inc.
Novartis AG
Nordion (Canada) Inc.
Jubilant Radiopharma

Key Coverage in the Radiopharmaceutical Market

Growth of the Radiopharmaceutical Market
demand for radiopharmaceuticals in Developing Countries
North America Radiopharmaceuticals Market
Industrial Analysis of Nuclear Medicine Market
Radiopharmaceuticals Demand Analysis

Key Segments Covered in the Radiopharmaceutical Industry Analysis

By Radioisotope Type:

Technetium-99
Fluorine-18
Iodine-131
Lutetium-177
Yttrium-90
Gallium-68
Gallium-67
Rubidium-82
Iodine-123
Iodine-125
Indium-111
Others

By Application:

Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others

By Source:

Cyclotrons
Nuclear Reactors

By End User:

Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Cancer Research Institute

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)

Frequently Asked Questions

How Much is the Radiopharmaceutical Market Currently Worth?

The radiopharmaceutical market is expected to be worth US$ 6972.1 million by 2024.

What is the Sales Forecast for Radiopharmaceuticals through 2034?

The radiopharmaceutical market is expected to reach US$ 11635 million by 2034.

At What Rate is the Radiopharmaceutical Market Expected to Grow?

The radiopharmaceutical market is expected to grow at a CAGR of 3.40% from 2024 to 2034.

Which are the key Companies in the Radiopharmaceutical Market?

Bayer AG, Bracco Imaging S.p.A., Cardinal Health, Inc., Eli Lilly and Company (Eli Lilly), Curium Pharma, etc., are some of the major players in the global radiopharmaceutical market.

What was the overall Value of the Radiopharmaceutical Market in 2023?

The valuation for the global radiopharmaceutical market in 2023 was US$ 6742.8 million.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Supply Chain Analysis

3.5.1. Supply Side Participants and their Roles

3.5.1.1. Manufacturer

3.5.1.2. Mid-Level Participants (Traders)

3.5.1.3. Distributors

3.5.2. Value Added and Value Created at Node in the Supply Chain

3.5.3. List of Raw Material Suppliers

3.5.4. List of Existing and Potential Buyer’s

3.6. Investment Feasibility Matrix

3.7. Value Chain Analysis

3.7.1. Profit Margin Analysis

3.7.2. Distributors

3.8. PESTLE and Porter’s Analysis

3.9. Regulatory Landscape

3.9.1. By Key Regions

3.9.2. By Key Countries

3.10. Regional Parent Market Outlook

3.11. Production and Consumption Statistics

3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2019 to 2023

4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2024 to 2034

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Radioisotope Type

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Radioisotope Type, 2019 to 2023

5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Radioisotope Type, 2024 to 2034

5.3.1. Technetium-99

5.3.2. Fluorine-18

5.3.3. Iodine-131

5.3.4. Leutetium-177

5.3.5. Yttrium-90

5.3.6. Gallium-68

5.3.7. Gallium-67

5.3.8. Rubidium-82

5.3.9. Iodine-123

5.3.10. Iodine-125

5.3.11. Indium-111

5.3.12. Others

5.4. Y-o-Y Growth Trend Analysis By Radioisotope Type, 2019 to 2023

5.5. Absolute $ Opportunity Analysis By Radioisotope Type, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Application, 2019 to 2023

6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Application, 2024 to 2034

6.3.1. Oncology

6.3.2. Cardiology

6.3.3. Gastroenterology

6.3.4. Neuroendocrinology

6.3.5. Neurology

6.3.6. Nephrology

6.3.7. Others

6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023

6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Source

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Source, 2019 to 2023

7.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Source, 2024 to 2034

7.3.1. Cyclotrons

7.3.2. Nuclear Reactors

7.4. Y-o-Y Growth Trend Analysis By Source, 2019 to 2023

7.5. Absolute $ Opportunity Analysis By Source, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User

8.1. Introduction / Key Findings

8.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By End User, 2019 to 2023

8.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By End User, 2024 to 2034

8.3.1. Hospitals

8.3.2. Diagnostic Imaging Centers

8.3.3. Ambulatory Surgical Centers

8.3.4. Cancer Research Institute

8.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023

8.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034

9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

9.1. Introduction

9.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2019 to 2023

9.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2024 to 2034

9.3.1. North America

9.3.2. Latin America

9.3.3. Western Europe

9.3.4. Eastern Europe

9.3.5. South Asia and Pacific

9.3.6. East Asia

9.3.7. Middle East and Africa

9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

10.2.1. By Country

10.2.1.1. USA

10.2.1.2. Canada

10.2.2. By Radioisotope Type

10.2.3. By Application

10.2.4. By Source

10.2.5. By End User

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Radioisotope Type

10.3.3. By Application

10.3.4. By Source

10.3.5. By End User

10.4. Key Takeaways

11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

11.2.1. By Country

11.2.1.1. Brazil

11.2.1.2. Mexico

11.2.1.3. Rest of Latin America

11.2.2. By Radioisotope Type

11.2.3. By Application

11.2.4. By Source

11.2.5. By End User

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Radioisotope Type

11.3.3. By Application

11.3.4. By Source

11.3.5. By End User

11.4. Key Takeaways

12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

12.2.1. By Country

12.2.1.1. Germany

12.2.1.2. UK

12.2.1.3. France

12.2.1.4. Spain

12.2.1.5. Italy

12.2.1.6. Rest of Western Europe

12.2.2. By Radioisotope Type

12.2.3. By Application

12.2.4. By Source

12.2.5. By End User

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Radioisotope Type

12.3.3. By Application

12.3.4. By Source

12.3.5. By End User

12.4. Key Takeaways

13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

13.2.1. By Country

13.2.1.1. Poland

13.2.1.2. Russia

13.2.1.3. Czech Republic

13.2.1.4. Romania

13.2.1.5. Rest of Eastern Europe

13.2.2. By Radioisotope Type

13.2.3. By Application

13.2.4. By Source

13.2.5. By End User

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Radioisotope Type

13.3.3. By Application

13.3.4. By Source

13.3.5. By End User

13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

14.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

14.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

14.2.1. By Country

14.2.1.1. India

14.2.1.2. Bangladesh

14.2.1.3. Australia

14.2.1.4. New Zealand

14.2.1.5. Rest of South Asia and Pacific

14.2.2. By Radioisotope Type

14.2.3. By Application

14.2.4. By Source

14.2.5. By End User

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Radioisotope Type

14.3.3. By Application

14.3.4. By Source

14.3.5. By End User

14.4. Key Takeaways

15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

15.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

15.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

15.2.1. By Country

15.2.1.1. China

15.2.1.2. Japan

15.2.1.3. South Korea

15.2.2. By Radioisotope Type

15.2.3. By Application

15.2.4. By Source

15.2.5. By End User

15.3. Market Attractiveness Analysis

15.3.1. By Country

15.3.2. By Radioisotope Type

15.3.3. By Application

15.3.4. By Source

15.3.5. By End User

15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

16.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

16.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

16.2.1. By Country

16.2.1.1. GCC Countries

16.2.1.2. South Africa

16.2.1.3. Israel

16.2.1.4. Rest of MEA

16.2.2. By Radioisotope Type

16.2.3. By Application

16.2.4. By Source

16.2.5. By End User

16.3. Market Attractiveness Analysis

16.3.1. By Country

16.3.2. By Radioisotope Type

16.3.3. By Application

16.3.4. By Source

16.3.5. By End User

16.4. Key Takeaways

17. Key Countries Market Analysis

17.1. USA

17.1.1. Pricing Analysis

17.1.2. Market Share Analysis, 2023

17.1.2.1. By Radioisotope Type

17.1.2.2. By Application

17.1.2.3. By Source

17.1.2.4. By End User

17.2. Canada

17.2.1. Pricing Analysis

17.2.2. Market Share Analysis, 2023

17.2.2.1. By Radioisotope Type

17.2.2.2. By Application

17.2.2.3. By Source

17.2.2.4. By End User

17.3. Brazil

17.3.1. Pricing Analysis

17.3.2. Market Share Analysis, 2023

17.3.2.1. By Radioisotope Type

17.3.2.2. By Application

17.3.2.3. By Source

17.3.2.4. By End User

17.4. Mexico

17.4.1. Pricing Analysis

17.4.2. Market Share Analysis, 2023

17.4.2.1. By Radioisotope Type

17.4.2.2. By Application

17.4.2.3. By Source

17.4.2.4. By End User

17.5. Germany

17.5.1. Pricing Analysis

17.5.2. Market Share Analysis, 2023

17.5.2.1. By Radioisotope Type

17.5.2.2. By Application

17.5.2.3. By Source

17.5.2.4. By End User

17.6. UK

17.6.1. Pricing Analysis

17.6.2. Market Share Analysis, 2023

17.6.2.1. By Radioisotope Type

17.6.2.2. By Application

17.6.2.3. By Source

17.6.2.4. By End User

17.7. France

17.7.1. Pricing Analysis

17.7.2. Market Share Analysis, 2023

17.7.2.1. By Radioisotope Type

17.7.2.2. By Application

17.7.2.3. By Source

17.7.2.4. By End User

17.8. Spain

17.8.1. Pricing Analysis

17.8.2. Market Share Analysis, 2023

17.8.2.1. By Radioisotope Type

17.8.2.2. By Application

17.8.2.3. By Source

17.8.2.4. By End User

17.9. Italy

17.9.1. Pricing Analysis

17.9.2. Market Share Analysis, 2023

17.9.2.1. By Radioisotope Type

17.9.2.2. By Application

17.9.2.3. By Source

17.9.2.4. By End User

17.10. Poland

17.10.1. Pricing Analysis

17.10.2. Market Share Analysis, 2023

17.10.2.1. By Radioisotope Type

17.10.2.2. By Application

17.10.2.3. By Source

17.10.2.4. By End User

17.11. Russia

17.11.1. Pricing Analysis

17.11.2. Market Share Analysis, 2023

17.11.2.1. By Radioisotope Type

17.11.2.2. By Application

17.11.2.3. By Source

17.11.2.4. By End User

17.12. Czech Republic

17.12.1. Pricing Analysis

17.12.2. Market Share Analysis, 2023

17.12.2.1. By Radioisotope Type

17.12.2.2. By Application

17.12.2.3. By Source

17.12.2.4. By End User

17.13. Romania

17.13.1. Pricing Analysis

17.13.2. Market Share Analysis, 2023

17.13.2.1. By Radioisotope Type

17.13.2.2. By Application

17.13.2.3. By Source

17.13.2.4. By End User

17.14. India

17.14.1. Pricing Analysis

17.14.2. Market Share Analysis, 2023

17.14.2.1. By Radioisotope Type

17.14.2.2. By Application

17.14.2.3. By Source

17.14.2.4. By End User

17.15. Bangladesh

17.15.1. Pricing Analysis

17.15.2. Market Share Analysis, 2023

17.15.2.1. By Radioisotope Type

17.15.2.2. By Application

17.15.2.3. By Source

17.15.2.4. By End User

17.16. Australia

17.16.1. Pricing Analysis

17.16.2. Market Share Analysis, 2023

17.16.2.1. By Radioisotope Type

17.16.2.2. By Application

17.16.2.3. By Source

17.16.2.4. By End User

17.17. New Zealand

17.17.1. Pricing Analysis

17.17.2. Market Share Analysis, 2023

17.17.2.1. By Radioisotope Type

17.17.2.2. By Application

17.17.2.3. By Source

17.17.2.4. By End User

17.18. China

17.18.1. Pricing Analysis

17.18.2. Market Share Analysis, 2023

17.18.2.1. By Radioisotope Type

17.18.2.2. By Application

17.18.2.3. By Source

17.18.2.4. By End User

17.19. Japan

17.19.1. Pricing Analysis

17.19.2. Market Share Analysis, 2023

17.19.2.1. By Radioisotope Type

17.19.2.2. By Application

17.19.2.3. By Source

17.19.2.4. By End User

17.20. South Korea

17.20.1. Pricing Analysis

17.20.2. Market Share Analysis, 2023

17.20.2.1. By Radioisotope Type

17.20.2.2. By Application

17.20.2.3. By Source

17.20.2.4. By End User

17.21. GCC Countries

17.21.1. Pricing Analysis

17.21.2. Market Share Analysis, 2023

17.21.2.1. By Radioisotope Type

17.21.2.2. By Application

17.21.2.3. By Source

17.21.2.4. By End User

17.22. South Africa

17.22.1. Pricing Analysis

17.22.2. Market Share Analysis, 2023

17.22.2.1. By Radioisotope Type

17.22.2.2. By Application

17.22.2.3. By Source

17.22.2.4. By End User

17.23. Israel

17.23.1. Pricing Analysis

17.23.2. Market Share Analysis, 2023

17.23.2.1. By Radioisotope Type

17.23.2.2. By Application

17.23.2.3. By Source

17.23.2.4. By End User

18. Market Structure Analysis

18.1. Competition Dashboard

18.2. Competition Benchmarking

18.3. Market Share Analysis of Top Players

18.3.1. By Regional

18.3.2. By Radioisotope Type

18.3.3. By Application

18.3.4. By Source

18.3.5. By End User

19. Competition Analysis

19.1. Competition Deep Dive

19.1.1. Siemens AG

19.1.1.1. Overview

19.1.1.2. Product Portfolio

19.1.1.3. Profitability by Market Segments

19.1.1.4. Sales Footprint

19.1.1.5. Strategy Overview

19.1.1.5.1. Marketing Strategy

19.1.1.5.2. Product Strategy

19.1.1.5.3. Channel Strategy

19.1.2. Positron Corporation

19.1.2.1. Overview

19.1.2.2. Product Portfolio

19.1.2.3. Profitability by Market Segments

19.1.2.4. Sales Footprint

19.1.2.5. Strategy Overview

19.1.2.5.1. Marketing Strategy

19.1.2.5.2. Product Strategy

19.1.2.5.3. Channel Strategy

19.1.3. Novartis (Advanced Accelerator Applications)

19.1.3.1. Overview

19.1.3.2. Product Portfolio

19.1.3.3. Profitability by Market Segments

19.1.3.4. Sales Footprint

19.1.3.5. Strategy Overview

19.1.3.5.1. Marketing Strategy

19.1.3.5.2. Product Strategy

19.1.3.5.3. Channel Strategy

19.1.4. Curium

19.1.4.1. Overview

19.1.4.2. Product Portfolio

19.1.4.3. Profitability by Market Segments

19.1.4.4. Sales Footprint

19.1.4.5. Strategy Overview

19.1.4.5.1. Marketing Strategy

19.1.4.5.2. Product Strategy

19.1.4.5.3. Channel Strategy

19.1.5. GE Healthcare

19.1.5.1. Overview

19.1.5.2. Product Portfolio

19.1.5.3. Profitability by Market Segments

19.1.5.4. Sales Footprint

19.1.5.5. Strategy Overview

19.1.5.5.1. Marketing Strategy

19.1.5.5.2. Product Strategy

19.1.5.5.3. Channel Strategy

19.1.6. Lantheus Holdings Inc.

19.1.6.1. Overview

19.1.6.2. Product Portfolio

19.1.6.3. Profitability by Market Segments

19.1.6.4. Sales Footprint

19.1.6.5. Strategy Overview

19.1.6.5.1. Marketing Strategy

19.1.6.5.2. Product Strategy

19.1.6.5.3. Channel Strategy

19.1.7. Sotera Health LLC (Nordion Inc.)

19.1.7.1. Overview

19.1.7.2. Product Portfolio

19.1.7.3. Profitability by Market Segments

19.1.7.4. Sales Footprint

19.1.7.5. Strategy Overview

19.1.7.5.1. Marketing Strategy

19.1.7.5.2. Product Strategy

19.1.7.5.3. Channel Strategy

19.1.8. Bayer AG

19.1.8.1. Overview

19.1.8.2. Product Portfolio

19.1.8.3. Profitability by Market Segments

19.1.8.4. Sales Footprint

19.1.8.5. Strategy Overview

19.1.8.5.1. Marketing Strategy

19.1.8.5.2. Product Strategy

19.1.8.5.3. Channel Strategy

19.1.9. Eckert & Ziegler

19.1.9.1. Overview

19.1.9.2. Product Portfolio

19.1.9.3. Profitability by Market Segments

19.1.9.4. Sales Footprint

19.1.9.5. Strategy Overview

19.1.9.5.1. Marketing Strategy

19.1.9.5.2. Product Strategy

19.1.9.5.3. Channel Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Radiopharmaceutical Market

Radiopharmaceutical Market Forecast by Technetium-99 and Fluorine-18 from 2024 to 2034